Top 50 Biotech VC (Venture Capital) Funds in Sweden in July 2025
A list of 50 VC (Venture Capital) funds that invest in Biotech startups based in Sweden. We rank investors based on the number of investments they made in Biotech companies from Sweden. We update this investor list every month.Top 50 Biotech VC (Venture Capital) Funds in Sweden in July 2025
Investor | Biotech Sweden investments |
---|---|
Sciety | 16 |
Chalmers Ventures AB | 15 |
Industrifonden | 11 |
Almi Invest | 11 |
Navigare Ventures | 6 |
HealthCap | 5 |
Karolinska | 5 |
SEB Venture Capital | 4 |
Norrsken VC | 4 |
Novo Holdings | 4 |
BackingMinds | 3 |
Voima Ventures | 3 |
Crowberry Capital | 3 |
Inventure | 3 |
Partnerinvest Norr | 3 |
Hadean Ventures | 2 |
Noaber | 2 |
Segulah Medical Acceleration | 2 |
Imprimatur Capital Fund Management | 2 |
Boehringer Ingelheim Venture Fund | 2 |
LIU Invest | 2 |
Nina Capital | 2 |
LU Holding | 2 |
Länsförsäkringar | 2 |
Faro Capital | 2 |
I Love Lund | 2 |
EIR Ventures | 2 |
Ysios Capital | 1 |
Irrus Investments | 1 |
Flerie Invest | 1 |
Impilo | 1 |
Nordic Foodtech VC | 1 |
Unruly Capital | 1 |
Glass Wall Syndicate | 1 |
Almi Invest GreenTech | 1 |
Innovations Kapital | 1 |
Bonnier Ventures | 1 |
Inter Ikea | 1 |
Social Starts | 1 |
GU Ventures | 1 |
Johnson & Johnson Innovation | 1 |
Northislet | 1 |
Karolinska Institutet Holding | 1 |
KTH Holding | 1 |
Fåhraeus Startup and Growth | 1 |
Kale United | 1 |
Annexstruktur | 1 |
Colibri Ventures | 1 |
Kurma Partners | 1 |
Inven2 | 1 |
Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Seed, Series A, Funding Round
- Sweden, Ukraine
Portfolio highlights
- Capitainer — Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually.
- PeptiSystems — PeptiSystems offers a new generation of instruments for solid-phase synthesis production of peptide and oligonucleotide therapeutics. Our instruments are used for process development and large-scale GMP and non-GMP manufacturing based on flowthrough column technology.
- TIRmed Pharma — TIRmed Pharma develops drug candidates addressing major clinical needs.
We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Pre-Seed, Seed, Funding Round
- Sweden
Portfolio highlights
- Embedl AB — Efficient Deep Learning by Deep Learning model optimization
- Adsorbi — Adsorbi use cellulose from the Nordic forest to help air purification companies to capture gaseous air pollutants.
- Swedish Algae Factory — Our algae materials replace harmful and less efficient chemicals in high-end organic personal care products and has the potential of increasing the efficiency of solar panels.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Funding Round, Series A, Seed
- Sweden, United States, Denmark
Portfolio highlights
- Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
- Gårdsfisk — Gårdsfisk is a company managing fishing farms. Gårdsfisks develops a new method for fish farming on land. The cultivation takes place in large pools in a closed system, where the nutrient residual water can be reused as fertilizer on the fields.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Almi Invest is Sweden’s most active early-stage venture capital firm, investing in scalable startups across Sustainability, Industry, Tech, and Life Science.We invest from pre-seed to Series A, always co-investing with independent private investors to accelerate innovation and long-term success. Our portfolio spans sustainable solutions,industrial innovation, deep tech, SaaS, and life science, supporting startups that drive economic and environmental progress.With €430 million under management and over 1,000 investments since 2009, we have backed leading companies like MIPS, Tobii, and Neo4j, with notable exits to Google, Apple, Microsoft, and Qlik.Beyond capital, we offer engaged ownership, providing strategic guidance, active board participation, and access to an extensive investor network.Almi Invest is part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners.
Show more
Investment focus
- Software, Health Care, Information Technology
- Funding Round, Seed, Pre-Seed
- Sweden, United States, United Kingdom
Portfolio highlights
- Embedl AB — Efficient Deep Learning by Deep Learning model optimization
- Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
- Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Funding Round, Seed, Series A
- Sweden, Denmark, United States
Portfolio highlights
- PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
- OssDsign AB — Giving patients back the life they deserve, Catalyst nanosynthetic bone graft, orthobiologics
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.
Show more
Investment focus
- Software, Information Technology, Financial Services
- Funding Round, Series A, Series B
- Sweden, Denmark, United Kingdom
Portfolio highlights
- EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
- Qvantum — Qvantum is driven by a passion for a sustainable future and we are changing the way the cities of Europe are heated.
- CorPower Ocean — CorPower Ocean is a turnkey supplier of wave energy systems, enabling customers to generate clean electricity from ocean waves - bringing stability to the renewable energy mix.
We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.
Show more
Investment focus
- Software, Food and Beverage, Health Care
- Seed, Series A, Funding Round
- Sweden, Germany, United Kingdom
Portfolio highlights
- Kapu — We are an online shopping community that helps you save even more on your everyday essentials when you buy together with your friends.
- trawa — The partner for renewable and affordable electricity for businesses. Get electricity directly from solar and windparks with corporate PPAs.
- Beans — Beans is on a mission to help the planet by reducing food waste, saving products, and offering them through an online grocery platform at discounted prices.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
We help great minds unleash their full potential!
Show more
Investment focus
- Medical Device, SaaS, Information Technology
- Seed, Funding Round, Pre-Seed
- Sweden, Denmark, Finland
Portfolio highlights
- NitroVolt — NitroVolt: the next generational step of sustainable ammonia.
- Serviceform — Welcome to future of communication - the truly all-in-one conversion and management software built for established businesses. Start now!
- Techarena — Since 2014 Techarena is the platform for innovation and Tech in the Nordics. From supporting startups and scaleups to bringing the Tech and Business world together at Scandinavia's Biggest Events.
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more
Investment focus
- Biotechnology, Health Care, Medical Device
- Seed, Pre-Seed, Funding Round
- Finland, Sweden, Norway
Portfolio highlights
- Hormona — Understand your hormones with the Hormona app. Monitor hormone levels, track symptoms, forecast cycles, and access personalized wellness tips for a balanced life.
- Epigenica — Epigenica focuses on advancing epigenomics through its EpiFinder™ platform, a multiplexed ChIP-seq technology for high-throughput analysis of epigenetic marks. The company offers R&D services for the development of therapeutic molecules and diagnostic methods using epigenetics. Epigenica aims to improve scientists' ability to capture andextract insights from the epigenome, contributing to precision medicine and the discovery of new biomarkers.
- Alba Health — Discover your baby's gut health & microbiome for the best start in life.
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more
Investment focus
- Software, Gaming, Health Care
- Seed, Series A, Pre-Seed
- Iceland, Denmark, Finland
Portfolio highlights
- Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
- Quanscient — We are building next generation simulation software-as-a-service utilizing Quantum computing algorithms. Our specialty domain of simulations is Computational Electromagnetics.
- Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- Finland, Sweden, Denmark
Portfolio highlights
- Hedera Dx — A diagnostics platform that makes liquid biopsies a reality in cancer care
- Moncyte Health — Unique technology and novel data for personalized and optimal treatment of high cholesterol
- Avenue Biosciences — From biotechnology tools to therapy discovery and development: Our platform enhances production yield and the quality of your end product.
Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors.
Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.
Show more
Investment focus
- Software, Information Technology, Manufacturing
- Seed, Funding Round, Series A
- Sweden, United States
Portfolio highlights
- Elastisys — Succeed with your cloud native journey as an organization developing and operating software critical to our society. NIS2, ISO-27001, GDPR.
- Senseworks — Senseworks is an insight platform that enables colleagues to collaborate effectively with customers by providing a single source of truth for accounting data.
- Cold River Games — Cold River Games is a Swedish game studio currently developing the ARPG Crystalfall.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
Noaber Ventures invests in initiatives that bring social transformations using information technology.
Show more
Investment focus
- Health Care, Medical, Fitness
- Seed, Series A, Funding Round
- The Netherlands, Israel, Sweden
Portfolio highlights
- Newsenselab (M-sense) — M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
- Elsa — Elsa is a platform for patient driven research for better drugs, health and prevention. Elsa lets patients become their own personal researchers by providing them with a better understanding around how lifestyle factors may affect their disease activity measurements for chronic disease. To support them from a scientific perspective, Elsa gives themaccess to data on their specific disease (initially we work with rheumatoid arthritis) through the Riskminder foundation and scientific studies at Karolinska Institutet.
- Alba Health — Discover your baby's gut health & microbiome for the best start in life.
Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Series A, Series D, Series B
- Sweden, Germany, United States
Portfolio highlights
- Protembis — ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR.The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures.Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR.Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.
- Navinci Diagnostics — Navinci is a Swedish biotech company specializing in innovative in situ proximity ligation assay-based solutions for spatial proteomics.
- Signifier Medical Technologies — Driving Innovation in the Sleep Market Signifier Medical Technologies (SMT) is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring. Pioneers in challenging the wisdom of conventional sleep apnoea and snoring treatments, we've created the first daytime therapy that tackles the root cause of sleep-disordered breathing by physiologically retraining the airway against collapse.
Imprimatur Capital Fund Management is a venture capital firm focusing on high-technology at an early stage in its commercial development. We invest in start-up technology businesses which are based on innovative intellectual property, are led by strong teams and have high international growth potential.Imprimatur Capital Fund Management, based inLatvia, manages seed and start-up funds with investors including the Latvian Guarantee Agency, other institutional investors and some private investors. The company source investment opportunities primarily from the Baltic/Nordic/Russia region.Imprimatur Capital Fund Management is a partner firm of Imprimatur Capital Ltd, headquartered in London and with investment operations in Europe, Russia, Asia Pacific, Latin America and the US.
Show more
Investment focus
- Software, Information Technology, Apps
- Seed, Debt Financing, Funding Round
- Latvia, United States, United Kingdom
Portfolio highlights
- Axial3D — Leading the way with the latest 3D imaging, models, and devices
- afriQloud — AfriQloud provides a white-labeled cloud computing solution to telecom operators, internet service providers, system integrators, and managed information technology service providers.
- Sonarworks — SoundID Reference software calibrates your speakers and studio headphones, so you can trust that every mix will translate.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.
Show more
Investment focus
- Biotechnology, Information Technology, Health Care
- Funding Round, Seed, Pre-Seed
- Sweden
Portfolio highlights
- Cellfion — Cellfion provides sustainable materials for next level clean energy storage and conversion devices.
- LunaMicro — Technology company developing textile pumps based on electroosmosis and conducting polymers for a wide variety of applications including outdoor clothing, PPE, and medicine.
- Polar Light Technologies — Polar Light Technologies focuses on developing the next generation of Nano and micro LED technology.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more
Investment focus
- Health Care, Artificial Intelligence, Medical
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Germany
Portfolio highlights
- CryoCloud — CryoCloud Accelerate your protein structure determination - Bring your cryo-EM data analysis to the next level by using our cloud-based image analysis workflow.
- Sonar — Sonar is a scalable mental health platform for schools. We use a combination of AI and human connection to ensure every student is seen and supported. For educators, Sonar offers actionable insights to improve mental wellbeing, empower your staff, and boost student outcomes.
- MedaSystems — Streamline patient and provider inquiries for Expanded Access or Compassionate Use with secure, 21st Century Cures Act compliant, cloud software.
LU Holding is a Lund University’s investment company.
Show more
Investment focus
- Biotechnology
- Pre-Seed
- Sweden
Portfolio highlights
- Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
- Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
Länsförsäkringar is a Swedish group of public insurance companies.
Show more
Investment focus
- Real Estate, Manufacturing, Apps
- Seed, Funding Round, Post-IPO Equity
- Sweden
Portfolio highlights
- Stendorren Fastigheter — Stendorren Fastigheter is a company involved in the real estate industry. It develops, owns, operates, and maintains industrial, logistical, and warehouse facilities. The business offers adequate and suitable space on fair lease terms through its tenant.
- Phenaros Pharmaceuticals — Data-centric drug discovery with AI, Phenomics and Automation.
- Swedish Logistic Property — Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities.
FARO is an Argentina company over 10 years of experience in the development and operation of integrated projects in the agribusiness sector. All projects FARO own position it as a reference and leader both locally and internationally.Among his various projects, FARO operates the largest tree planting pecan nut Latin America, with projection tobecome the largest southern hemisphere and one of the largest in the world. This project is structured under different vehicles, including Alto Pecan stands, the first real estate development of nautical fields planted with pecan nut Latin America, located in Villa Paranacito, Entre Ríos . Another project is AgroConsortium, productive trust for the production and marketing of cereals and oilseeds in leased farms located in different productive areas in Argentina and potentially in the region. Finally, thanks to the expertise acquired in agribusiness, FARO developed his own business model for productive land conversion. Its aim is to position rural properties whose productive potential is not reflected in the price and complement the cycle with the economic use of land in intensive production, short and medium term.Since 2006, the Investor Group is a strategic partner OMBU FARO for all investment portfolios development ventures related to agribusiness, that focus on supply both local and international markets.
Show more
Investment focus
- Biotechnology, Gaming, Medical
- Series A, Seed, Funding Round
- Sweden, United States
Portfolio highlights
- Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
- Bluwhale — Unlock Web3 Wallet Potential with AI Insights. Supercharge Your Business Growth
- IntuiCell — IntuiCell develops a fundamentally new recursive computing architecture and associated technology platform.
I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds
Show more
Investment focus
- Analytics, Biotechnology, Market Research
- Seed, Pre-Seed, Funding Round
- Sweden
Portfolio highlights
- Bionamic — Bionamic provides solutions for the analysis of life science data to reduce or eliminate the manual steps between raw data and results.
- Parlametric — Parlametric is a research-based company that specializes in analytics, business intelligence, and market research services.
- Trackpaw Scientific — Contributing to the development of safe and effective pharmaceuticals at increased speed and quality by digitalising the preclinical study landscape.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Funding Round
- Denmark, Sweden, United States
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- ArgusEye — ArgusEye - Innovative Sensor Solutions - Real-time monitoring and control of biological systems and processes - Patented sensor technology
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Spain, United States, Switzerland
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.
Show more
Investment focus
- Medical Device, Biotechnology, Health Care
- Seed, Funding Round, Series A
- Ireland, Sweden, United States
Portfolio highlights
- Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
- CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
- SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer.
Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Funding Round, Series B
- Sweden, Israel, Iceland
Portfolio highlights
- Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
- Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
- Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.
Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Its starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which theyoperate in order to remain successful in the long term. It was founded in 2017 and is based in 2017 and is based in Stockholm, Sweden.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Medical
- Funding Round
- Sweden, Denmark
Portfolio highlights
- Cavidi — Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of theworld’s leading labs.Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Their expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today their focus is on HIV but our methods and expertise can be applied to other viruses.Cavidi’s head office is in Uppsala, Sweden and they have sales offices in South Africa, India and USA. Their customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.
- Scantox — Since 1977 Scantox has been a trusted partner for in-vivo preclinical research services for the pharmaceutical and medical device industries.
- Pelago Bioscience — Pelago Bioscience offers target engagement studies of drug candidate interactions with target proteins in cells and tissues.
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more
Investment focus
- Biotechnology, Life Science, Water
- Seed, Series A, Funding Round
- Finland, Sweden, Denmark
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Endless Food — Endless Food Co is a food innovation firm focusing on the junction of pleasure and sustainability. Endless Food Co was pulled together by a common idea that the transition to a greener and more egalitarian future food system will be driven by flavor, and having spent the last decade pioneering sustainable gastronomy
- Happy Plant Protein — Changing the way plant proteins are made
Investing in the crazy before it becomes normal
Show more
Investment focus
- Biotechnology, CleanTech, Manufacturing
- Seed, Pre-Seed, Funding Round
- United Kingdom, United States, Germany
Portfolio highlights
- Ephos — Designing and manufacturing glass-based integrated photonic circuits that power the most advanced classical and quantum devices
- AtmoCooling — AtmoCooling transforms coastal deserts into thriving hubs of agriculture, clean energy, and climate resilience. It was founded in 2022 and operates in the USA and UAE.
- Terran Robotics — Terran Robotics is a construction company that specializes in AI and robotics. The company's headquarters are in Bloomington, Indiana.
Glass Wall Syndicate invests in companies and products that will make a difference in the lives of animals, people, and the planet. It helps grow companies in this space by providing them with capital, resources, mentorship, and other forms of support.The firm is consists of a group of venture capitalists, foundations, trusts, non-profits, andindividual investors who share a similar investment thesis and want to accelerate mainstream adoption of products and services that will make a difference in the lives of animals, people and that are better for the planet.
Show more
Investment focus
- Biotechnology, Health Care, Food and Beverage
- Seed, Pre-Seed, Series C
- United States, India, Sweden
Portfolio highlights
- MeliBio — Discover MeliBio's innovative bee-free honey, promoting a sustainable future for humans and bees. Explore our mission, vision, and impact.
- Evo Foods — EVO foods is creating India’s first 100% plant based liquid egg
- Cultured Decadence — Growing real meat directly from animal cells.
Almi Invest GreenTech is a venture capital company and an active start-up investor.
Show more
Investment focus
- Waste Management, Energy, Manufacturing
- Funding Round, Seed, Series A
- Sweden
Portfolio highlights
- Zparq — Zparq designs and manufactures marine electric propulsion products.
- Modvion — Modvion is a Swedish/ American Engineering and Industrial Design company developing modular designs in renewable engineered wood product materials to simplify and improve construction logistics.Their current area of focus is in wind tower technology. Modvion´s patented module technology enables significantly decreased cost, efficienttransportation and streamlined installation of towers exceeding 120 m. Ultimately, this results in increased cost efficiency in the harvesting of wind resources.
- EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Series B, Series C
- Sweden, Denmark, United States
Portfolio highlights
- Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Bonnier Capital is the investment division of the Bonnier Group. Since 2016, we invest in promising companies in structurally growing industries and have become a reliant investment partner to companies and funds of various sizes.
Show more
Investment focus
- Health Care, Digital Media, Software
- Funding Round, Seed, Series A
- Sweden, Finland, Germany
Portfolio highlights
- Combify — Combify is a PropTech company that works with simplifying the communication in city development projects.
- Natural Cycles — Natural Cycles birth control is 93% effective with typical use and 98% effective with perfect use. Learn more about hormone-free birth control today.
- Kyra — Kyra is a Gen-Z entertainment company creating engaging digital content that resonates with youth culture. We represent world class digital native talent, produce digital content with the biggest and best consumer brands and develop media properties publishing daily content on platforms that matter to Gen Z. Kyra has the ability to not onlytarget but truly engage with the Gen-Z audience through content that resonates based on real-time audience data from our proprietary KyraIQ technology. Our inclusive, ahead-of-the-trend content and content creators make us the ultimate destination for the Gen-Z consumer who wants to be inspired by their own community. Our approach and creativity is based on data and insights and has proven to engage this audience better than any traditional publisher. We house a talent agency representing and collaborating with the leading Gen Z social stars such as Abby Roberts and Noen Eubanks; a global content studio creating award-winning content for youth-seeking brand partners such as Converse and HP; and a newly developed portfolio of media properties publishing daily content on Gen Z-native platforms around beauty, fashion, adventure, food, gaming and entertainment.Kyra engages Gen Z better than any traditional publisher, with an audience of 78 million social media followers racking up 750 million monthly video views in 190 countries around the globe. We know exactly where Gen Z is spending their time online and we respect their interests and passions. That result is content that is meaningful and fosters long term engagement for blue chip brands. Our team are experts on Gen Z culture, whether they are producing, managing, creating or marketing in New York, London and Los Angeles. Learn more at https://kyra.com/reel
Inter IKEA Group's aim is to secure continuous improvement, development, expansion and a long life of the franchising operation.
Show more
Investment focus
- Software, Furniture, Health Care
- Funding Round, Seed, Corporate Round
- Germany, Sweden, Denmark
Portfolio highlights
- nyris — Our custom search engines make it easy for people to find products, spare parts, and components for industry and eCommerce
- NORNORM — High quality pre-loved office furniture, including office design, installation and flexibility to change. Own less, pay less, and change whenever.
- Seprify — Enabling sustainable products
Social Starts is a $60M+ venture capital partnership with a uniquely data-driven approach to investing in moment-of-inception and Series A financing rounds.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Seed, Series A, Funding Round
- United States, Germany, United Kingdom
Portfolio highlights
- Hey Jane — Get safe, effective and affordable abortion pills delivered fast to your home. Hey Jane is the first digital abortion clinic, connecting you to licensed providers in your state through telemedicine.
- Mae Health — Mae is a maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes.
- Wayfinder Biosciences — We design RNA for next generation biomanufacturing and smart therapeutics.
GU Ventures build businesses out of groundbreaking ideas that help shape a better tomorrow. Our passionate team of company builders, financial experts, IP and legal talent ensure success for our companies.
Show more
Investment focus
- Health Care, Pharmaceutical, Eyewear
- Seed, Funding Round
- Sweden
Portfolio highlights
- OnDosis — An intuitive dosage manager that helps patients optimize their treatment outcomes. Closing the loop between patient and physician.
- Profundus Imaging — Profundus' retinal imaging technology enables researchers and clinicians in particular to visualise subclinical changes of retinal disease.
- Thioredoxin Systems — Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Israel, France
Portfolio highlights
- Stylus Medicine — Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.
- PAQ Therapeutics — PAQ Therapeutics is developing KRAS degraders for deadly cancers without good treatment options.
- Prazer Therapeutics — Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology.
North islet Tech & Life Science Investments Learn More
Show more
Investment focus
- Biotechnology
- Funding Round
- Sweden
Portfolio highlights
- BioLamina — BioLamina offers laminin cell culture matrix, the only laminins that are the original, full length, human recombinant laminins on the market.
- AAX Biotech — AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. OurTechnologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.
Karolinska Institutet Holding is a subsidiary of KI Holding AB.
Show more
Investment focus
- Biopharma, Biotechnology, Pharmaceutical
- Seed
- Sweden
Portfolio highlights
- AAX Biotech — AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. OurTechnologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.
KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Funding Round, Seed, Pre-Seed
- Sweden
Portfolio highlights
Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.
Show more
Investment focus
- Medical, Health Care, Organic Food
- Funding Round, Seed
- Sweden
Portfolio highlights
- Aplagon — Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.
- Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
- Nygen Analytics — Nygen empowers researchers to unlock insights from single-cell RNA-seq data with accessible, no-code solutions, facilitating reproducible transcriptomic research.
Kale United offers a portfolio of over 75+ plant-based game changers
Show more
Investment focus
- Food and Beverage, Food Processing, Biotechnology
- Seed, Pre-Seed, Funding Round
- United Kingdom, Sweden, India
Portfolio highlights
- Loki Foods — We're producing sustainable, plant-based foods from the Arctic. Iceland’s first plant-based cod and seafood!
- THE PACK — Nutritionally complete vegan dog food. Grain-free & developed with food scientists & animal nutritionists, try our delicious vegan dog food now.
- Swedish Temptations — Swedish Temptations, founded in 2019 by CEO Pia Qvarnström, built a brand named Bärta for producing organic, vegan and fermented food. The ingredients include Swedish split peas.
Annexstruktur is a venture capital firm that provides investments to companies.
Show more
Investment focus
- Medical, Life Science, Biotechnology
- Series A
- Sweden
Portfolio highlights
- Thioredoxin Systems — Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The
Colibri Ventures invest in early-stage life science companies and help accelerate their innovations into commercial products.
Show more
Investment focus
- Gaming, Wellness, Health Care
- Seed, Series A, Funding Round
- Sweden, Mexico
Portfolio highlights
- Mundi — Mundi provides financial, trade development, strategy, freight and reinventing international trade services.
- Mindforce Game Lab — Mindforce Game Lab creates meaningful games with characters that act as companions on the journey to better health.
- Pixelgen Technologies — Understand the role of proteins in cellular organization with spatial proteomics. Get ahead in the field of proteomics with us.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Series A, Series B, Seed
- France, Spain, Switzerland
Portfolio highlights
- Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
- Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Inven2 specializes in the commercialization of research and to make outstanding research into the industry of the future.
Show more
Investment focus
- Therapeutics, Biotechnology, Pharmaceutical
- Series A
- Sweden
Portfolio highlights
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Investors by industry
Consumer
Proptech
Impact
Climate
Gaming
Biotech
FinTech
Marketplace
Community
Health Care
Hardware
Energy
Artificial intelligence
Google
EdTech
Sustainability
Venture Capital
Real Estate
Photography
Clean Energy
Education
B2B
Financial Services
Big Data
Payments
Finance
Organic Food
Food and Beverage
Web3
Infrastructure
Retail
Beauty
Publishing
Video Games
Music
Art
Wellness
Franchise
Mobile
Local
Digital Media
Legal
Android
eSports
Enterprise Software
Sports
Manufacturing
Email
Medical
Social Network
Social Media
Internet
Construction
Hospitality
Platforms
Biotechnology
Cannabis
Mobile Advertising
Travel
Fitness
Recruiting
Crowdfunding
Social
Medical Device
Automotive
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Canada
Germany
United Kingdom
Ireland
South Korea
India
Australia
New Zealand
United States
Middle East
Brazil
LATAM
Qatar
Indonesia
Asia
Europe
Spain
South Africa
Singapore
Armenia
Saudi Arabia
Sri Lanka
China
Africa
Oceania
Belarus
Chile
Japan
Belgium
Vietnam
Hong Kong
Finland
Ghana
Kuwait
Georgia
Ethiopia
Gibraltar
Malta
Faroe Islands
Denmark
Egypt
Morocco
Estonia
Costa Rica
Hungary
Greece
Barbados
Nicaragua
Croatia
Belize
Bahrain
Czech Republic
Algeria
Ecuador
Mali
Bulgaria
Lithuania
Bermuda
France
Poland
Senegal
Sierra Leone
Tunisia
Peru
Togo
Serbia
Turkey
Lebanon
San Marino
Thailand
Jersey
Uzbekistan
Taiwan
Norway
Sweden
Tanzania
Slovenia
El Salvador
Myanmar
Portugal
Tajikistan
Ukraine
Puerto Rico
Mauritius
Uganda
Venezuela
Uruguay
Zambia
Zimbabwe
Rwanda
Russian Federation
Dominican Republic
Liberia
Nigeria
Iraq
Azerbaijan
Bahamas
Iceland
Namibia
Mexico
United Arab Emirates
Jamaica
Honduras
Malaysia
Bolivia
Isle of Man
Luxembourg
Liechtenstein
Albania
Pakistan
Philippines
Italy
Grenada
Jordan
Bangladesh
Argentina
Romania
Israel
Panama
Kenya
Kazakhstan
Cayman Islands
Cambodia
Latvia
Cyprus
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Seychelles
Marshall Islands
VC (Venture Capital) Funds in Sweden by industry
Financial Services
Big Data
Cryptocurrency
Finance
Payments
Organic Food
Restaurants
Food and Beverage
Medical
Medical Device
Biotechnology
Wellness
Internet
Social Media
Email
Manufacturing
Art
Social Network
Digital Media
Music
Mobile
Android
Legal
Construction
Software
Sports
eSports
Fitness
Hospitality
CleanTech
Travel
Automotive
InsurTech
Recruiting
FinTech
Enterprise
Consumer
Sustainability
EdTech
Climate
Energy
SaaS
Impact
Proptech
Marketplace
Artificial intelligence
Community
Hardware
Gaming
Retail
Infrastructure
Fashion
Web3
B2B
Life Science
Video Games
Photography
Publishing
Wine And Spirits
Education
Clean Energy
Renewable Energy
Real Estate
Biotech
Enterprise Software
Transportation
Health Care
Social Impact
Mobile Apps
Blockchain
Media (entertainment)
Agriculture (agtech)
Machine Learning
Platforms